Medication review in cancer pain management: A patient safety framework for optimizing pain control and reducing medication-related harm/adverse drug events [0.03%]
癌症疼痛管理中的药物评估：用于优化止痛和减少与药物相关的损害/不良事件的患者安全框架
Sunil Shrestha,Ajaya Acharya,Nabin Pathak et al.
Sunil Shrestha et al.
ObjectiveThis article proposes a structured, practice-oriented medication review framework designed to optimize pain control and reduce medication-related harm in patients with cancer. By repositioning medication review as the central, deci...
Longitudinal opioid utilisation trajectories and domain-specific quality of life in advanced cancer pain: A prospective cohort study using group-based trajectory modelling [0.03%]
纵向队列研究：阿片类药物使用轨迹与晚期癌症疼痛患者的生活质量关系
Kavshik K B,Rakesh M,Prince Alex Abraham et al.
Kavshik K B et al.
BackgroundOpioid therapy is the cornerstone of advanced cancer pain management, yet requirements vary considerably between patients over time. Identifying distinct longitudinal opioid utilisation phenotypes and their relationship with quali...
Opioid-induced respiratory depression or oversedation risk assessment in hospitalized patients with cancer receiving palliative care [0.03%]
住院接受姑息治疗的癌症患者的阿片类诱导呼吸抑制或过度镇静风险评估
Nancy Baballos,Levon S Shahnazarian,Larsa A Goro et al.
Nancy Baballos et al.
PurposeThe Oversedation Risk Criteria (ORC) is a prediction model that estimates prescription opioid-induced respiratory depression (OIRD) or oversedation risk in hospitalized patients. The study objectives were to estimate OIRD/oversedatio...
A real-world pharmacovigilance analysis of cardiac adverse events associated with newer antibody-drug conjugates for hematological malignancies in adults: A disproportionality analysis from FDA adverse event reporting system database [0.03%]
基于真实世界药物警戒的成人血液系统肿瘤新型抗体偶联药物心脏不良事件的信号检测：来自美国食品药品管理局不良事件数据库的 disproportionality 分析
Deepika Dilip,Pritika Sharma,Elizabeth Drugge et al.
Deepika Dilip et al.
IntroductionAntibody-drug conjugates (ADCs) are cancer therapies that deliver cytotoxic agents to tumor cells. Despite their specificity, toxicity remains a concern. Cardiac adverse events (CAEs) have not been studied in prospective trials,...
Dementia as a rare neurological adverse event of Nivolumab in a patient with metastatic renal cell carcinoma [0.03%]
一例接受尼伏单抗治疗的转移性肾细胞癌患者出现罕见神经不良反应——痴呆症
Gulhan Dinc
Gulhan Dinc
BackgroundImmune checkpoint inhibitors (ICIs) have transformed cancer therapy but can cause immune-related adverse events (irAEs). Neurological irAEs are rare, and dementia associated with nivolumab has been rarely reported.Case Presentatio...
Comparison of H1 versus combined H1/H2 antagonist premedication on incidence of rituximab infusion-related reaction: A retrospective cohort study [0.03%]
利托昔单抗输液反应的危险因素及西咪替丁联合雷尼替丁预防输液反应的有效性：回顾性队列研究
Ngan N Nguyen,Hannah M Kisla,Mark Sorial et al.
Ngan N Nguyen et al.
IntroductionRituximab, an anti-CD20 monoclonal antibody used in B-cell malignancies, is associated with infusion-related reactions (IRRs) during the initial infusion. Standard premedication includes acetaminophen, corticosteroids, and a his...
Beyond neutrality in LGBTQIA+ cancer care: Optimising outcomes through inclusive and culturally competent pharmacy practice [0.03%]
超越中立：通过包容性和文化胜任力的药学实践优化LGBTQIA+癌症护理结局
Sunil Shrestha,Nabin Pathak,Ajaya Acharya et al.
Sunil Shrestha et al.
ObjectiveTo examine the pharmacological and psychosocial complexities in LGBTQIA+ cancer care and to highlight the role of pharmacists in delivering inclusive, culturally competent care to optimise treatment outcomes.Data sourcesA comprehen...
Reduced-dose venetoclax through intentional CYP inhibition: A reproducible global access strategy with drug price as the residual barrier [0.03%]
通过故意抑制CYP酶降低维奈克拉剂量：一种可重复的全球准入策略，药物价格仍是剩余障碍
Fernando De la Garza-Salazar
Fernando De la Garza-Salazar
Beyond the standard 80 mg: Exposure-guided and equity-oriented precision dosing of Osimertinib in EGFR-mutant NSCLC [0.03%]
奥西替尼治疗EGFR突变型NSCLC的精准给药策略：从80 mg起始后的以药物暴露为导向和注重公平性的剂量调整策略
Manojkumar V,Dhivya Dhanasekaran,Arun Kp
Manojkumar V
BackgroundOsimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has become foundational therapy across the EGFR-mutant non-small cell lung cancer (NSCLC) continuum, including first-line metas...
Managing aseptic capacity pressures in systemic anti-cancer therapy services: A national mixed-methods evaluation of UK SACT board guidance implementation [0.03%]
英国SACT委员会指导实施的全国混合方法评估：管理系统性抗癌治疗服务的无菌容量压力
Annette Netty Cracknell,Dharmisha Chauhan,Lisa Barrott et al.
Annette Netty Cracknell et al.
IntroductionDemand for systemic anti-cancer therapy (SACT) is increasing, placing pressure on cancer services, particularly aseptic capacity. Aseptic preparation is a safety-critical, regulated component of SACT delivery, and constraints po...